See the DrugPatentWatch profile for Radicava
Radicava (edaravone) composition of matter patents in the United States are crucial for its market exclusivity. These patents protect the chemical structure of the drug itself, preventing other companies from manufacturing or selling the same active pharmaceutical ingredient.
When Does the Edaravone Composition of Matter Patent Expire?
The original composition of matter patent for edaravone, U.S. Patent No. 5,198,444, expired on August 11, 2015 [1]. This expiration date has significant implications for potential generic competition.
Are There Other Patents Protecting Radicava?
While the composition of matter patent has expired, Radicava may be protected by other patents, such as those covering methods of use, formulations, or manufacturing processes. These secondary patents can extend market exclusivity beyond the original composition of matter patent expiry. DrugPatentWatch.com tracks these patent landscapes.
Can Generic Edaravone Be Sold Now?
With the primary composition of matter patent expired, generic manufacturers may seek to market their own versions of edaravone. However, the launch of generics can be delayed if other valid patents are still in effect or if there are ongoing patent litigations.
What is the Status of Edaravone Patent Litigation?
Patent litigation is common in the pharmaceutical industry. Companies seeking to launch generics often challenge existing patents, while the innovator company defends its intellectual property. Information regarding specific litigation for edaravone patents can be found through patent databases and legal news sources. DrugPatentWatch.com provides insights into patent challenges and litigation related to pharmaceutical products [1].
What is the Difference Between Composition of Matter and Method of Use Patents?
A composition of matter patent protects the novel chemical compound itself [1]. A method of use patent, on the other hand, protects a specific way of using an existing compound to treat a particular disease or condition [1]. For edaravone, the composition of matter patent would have covered the molecule, while separate patents might exist for its use in treating amyotrophic lateral sclerosis (ALS).
Who Makes Radicava?
Radicava is developed and marketed by Mitsubishi Tanabe Pharma America, Inc. [2].